Vical extends patent coverage for Vaxfectin adjuvant

By Elaine Rigoli

Tampa, Fla., Sept. 13 - Vical, Inc. announced the issuance of U.S. Patent No. 7,105,574 covering both the novel Vaxfectin adjuvant and its use with conventional vaccines against infectious diseases and cancer.

The company holds previously issued patents in the United States and Europe covering the use of Vaxfectin with DNA vaccines.

"Adjuvants are commonly included in vaccines to enhance immune responses or to reduce dosing. Currently, the only adjuvant broadly used in human vaccines in the United States is alum, which has not changed significantly in more than 50 years," said Vijay B. Samant, president and chief executive officer, in a statement.

"Vaxfectin is a key component of our avian flu DNA vaccine because of its superiority in animal models. We are exploring the potential of Vaxfectin as a dose-sparing adjuvant for conventional avian pandemic flu vaccines as well."

The San Diego biopharmaceutical company said Vaxfectin formulations have demonstrated safety and adjuvant activity in DNA vaccine applications in multiple animal models, including non-human primates.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.